UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Screening and Prostate-Cancer Mortality in a Randomized European Study

The New England journal of medicine, 2009-03, Vol.360 (13), p.1320-1328

2009

Volltextzugriff (PDF)

Screening for Prostate Cancer: Results of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer

European urology, 2013-10, Vol.64 (4), p.530-539

2013

Volltextzugriff (PDF)

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer

European journal of cancer (1990), 2010-11, Vol.46 (17), p.3109-3119

2010

Volltextzugriff (PDF)

PROSTATE CANCER DETECTION IN THE PROSTATE SPECIFIC ANTIGEN RANGE OF 2.0 TO 3.9 NG/ML: VALUE OF PERCENT FREE PROSTATE SPECIFIC ANTIGEN ON TUMOR DETECTION AND TUMOR AGGRESSIVENESS

The Journal of urology, 2004-06, Vol.171 (6), p.2245-2249

2004

Volltextzugriff (PDF)

hK2 and Free PSA, a Prognostic Combination in Predicting Minimal Prostate Cancer in Screen-Detected Men within the PSA Range 4–10 ng/ml

European urology, 2007-11, Vol.52 (5), p.1358-1364

2007

Volltextzugriff (PDF)

Prostate-Cancer Mortality at 11 Years of Follow-up

The New England journal of medicine, 2012-03, Vol.366 (11), p.981-990

2012

Volltextzugriff (PDF)

Additional use of [−2] precursor prostate-specific antigen and “benign” PSA at diagnosis in screen-detected prostate cancer

Urology (Ridgewood, N.J.), 2005-05, Vol.65 (5), p.926-930

2005

Volltextzugriff (PDF)

PROSTATE CANCER CHARACTERISTICS AND PROSTATE SPECIFIC ANTIGEN CHANGES IN SCREENING DETECTED PATIENTS INITIALLY TREATED WITH A WATCHFUL WAITING POLICY

The Journal of urology, 2004-12, Vol.172 (6), p.2193-2196

2004

Volltextzugriff (PDF)

The Free-To-Total Prostate Specific Antigen Ratio Improves the Specificity of Prostate Specific Antigen in Screening for Prostate Cancer in the General Population

The Journal of urology, 1997-06, Vol.157 (6), p.2191-2196

1997

Volltextzugriff (PDF)

Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men

World journal of urology, 2007-03, Vol.25 (1), p.95-103

2007

Volltextzugriff (PDF)

Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir

Journal of acquired immune deficiency syndromes (1999), 2003-02, Vol.32 (2), p.135-142

2003

Volltextzugriff (PDF)

The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men

Urology (Ridgewood, N.J.), 1995-12, Vol.46 (6), p.773-778

1995

Volltextzugriff (PDF)

Rotterdam Randomized Pilot Studies of Screening for Prostate Cancer—An Overview After 10 Years

JNCI : Journal of the National Cancer Institute, 2005-05, Vol.97 (9), p.696-696

2005

Volltextzugriff (PDF)

Technical performance and diagnostic utility of the new elecsys® neuron-specific enolase enzyme immunoassay

Clinical chemistry and laboratory medicine, 2003-01, Vol.41 (1), p.95-103

2003

Volltextzugriff (PDF)

Comparison of Two Assays for Human Kallikrein 2

Clinical chemistry (Baltimore, Md.), 2003-02, Vol.49 (2), p.243-247

2003

Volltextzugriff (PDF)

New developments in the standardization of total prostate-specific antigen

Clinical biochemistry, 1999-11, Vol.32 (8), p.627-634

1999

Volltextzugriff (PDF)

Analytical issues on prostate-specific antigen in relation to prostate cancer screening

Clinical biochemistry, 1998-11, Vol.31 (8), p.633-639

1998

Volltextzugriff (PDF)

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer: Screening for Prostate Cancer; Lessons Learnt from the European Randomised Study of Screening for Prostate Cancer

European journal of cancer (1990), 2010, Vol.46 (17), p.3109-3119

2010

Volltextzugriff (PDF)

The Free-To-Total Prostate Specific Antigen Ratio Improves the Specificity of Prostate Specific Antigen in Screening for Prostate Cancer in the General Population

The Journal of urology, 1997-06, p.2191-2196

1997

Volltextzugriff (PDF)

The Free-to-Total Serum Prostate Specific Antigen Ratio for Staging Prostate Carcinoma

The Journal of urology, 1997-02, Vol.157 (2), p.544-547

1997

Volltextzugriff (PDF)

The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density

Urology (Ridgewood, N.J.), 1995-12, Vol.46 (6), p.779-784

1995

Volltextzugriff (PDF)

1660: Propsa Improves Prostate Cancer Detection and Tumor Aggressiveness in PSA Range 2.0 - 3.9 NG/ML

The Journal of urology, 2004-04, Vol.171 (4), p.439-439

2004

Volltextzugriff (PDF)

European randomized study of screening for prostate cancer—The Rotterdam pilot studies

International journal of cancer, 1996-01, Vol.65 (2), p.145-151

1996

Volltextzugriff (PDF)

On the Standardization of Total Prostate-Specific Antigen: an Exercise with Two Reference Preparations

Clinical chemistry and laboratory medicine, 1999-05, Vol.37 (5), p.545-552

1999

Volltextzugriff (PDF)

Some Analytical Considerations on the Measurement of Prostate-Specific Antigen

Clinical chemistry and laboratory medicine, 1996, Vol.34 (10), p.817-822

1996

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(36)

Sprache

Englisch
(36)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Screening and Prostate-Cancer Mortality in a Randomized European Study

Screening for Prostate Cancer: Results of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer

PROSTATE CANCER DETECTION IN THE PROSTATE SPECIFIC ANTIGEN RANGE OF 2.0 TO 3.9 NG/ML: VALUE OF PERCENT FREE PROSTATE SPECIFIC ANTIGEN ON TUMOR DETECTION AND TUMOR AGGRESSIVENESS

hK2 and Free PSA, a Prognostic Combination in Predicting Minimal Prostate Cancer in Screen-Detected Men within the PSA Range 4–10 ng/ml

Prostate-Cancer Mortality at 11 Years of Follow-up

Additional use of [−2] precursor prostate-specific antigen and “benign” PSA at diagnosis in screen-detected prostate cancer

PROSTATE CANCER CHARACTERISTICS AND PROSTATE SPECIFIC ANTIGEN CHANGES IN SCREENING DETECTED PATIENTS INITIALLY TREATED WITH A WATCHFUL WAITING POLICY

The Free-To-Total Prostate Specific Antigen Ratio Improves the Specificity of Prostate Specific Antigen in Screening for Prostate Cancer in the General Population

Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men

Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir

The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men

Rotterdam Randomized Pilot Studies of Screening for Prostate Cancer—An Overview After 10 Years

Technical performance and diagnostic utility of the new elecsys® neuron-specific enolase enzyme immunoassay

Comparison of Two Assays for Human Kallikrein 2

New developments in the standardization of total prostate-specific antigen

Analytical issues on prostate-specific antigen in relation to prostate cancer screening

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer: Screening for Prostate Cancer; Lessons Learnt from the European Randomised Study of Screening for Prostate Cancer

The Free-To-Total Prostate Specific Antigen Ratio Improves the Specificity of Prostate Specific Antigen in Screening for Prostate Cancer in the General Population

The Free-to-Total Serum Prostate Specific Antigen Ratio for Staging Prostate Carcinoma

The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density

1660: Propsa Improves Prostate Cancer Detection and Tumor Aggressiveness in PSA Range 2.0 - 3.9 NG/ML

European randomized study of screening for prostate cancer—The Rotterdam pilot studies

On the Standardization of Total Prostate-Specific Antigen: an Exercise with Two Reference Preparations

Some Analytical Considerations on the Measurement of Prostate-Specific Antigen

Suchergebnisse filtern